Asian Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT newswire2026/10/05 14:3710:37 AM EDT, 10/05/2026 (MT Newswires) -- Asian equities traded in the US as American depositary receipts started the week higher Monday morning, rising 0.67% to 3,009.64 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by internet and data center services provider VNET Group (VNET) and fintech firm Qfin (QFIN), which rose 5.8% and 5.5% respectively. They were followed by education companies 51Talk Online Education Group (COE) and Four Seasons Education (FEDU), which were up 3.4% and 3.3% respectively. The decliners from North Asia were led by education company 17 Education & Technology Group (YQ) and semiconductor company Himax Technologies (HIMX), which fell 4.3% and 2.7% respectively. They were followed by game live-streaming service HUYA (HUYA) and solar panel maker JinkoSolar (JKS), which were down 1.3% and 1.2% respectively. From South Asia, the gainers were led by telecommunications operator Telekomunikasi Indonesia (TLK) and tech conglomerate Sea (SE), which advanced 2.4% and 2.2% respectively. They were followed by lender ICICI Bank (IBN) and telecommunications operator PLDT (PHI), which increased 1% and 0.3% respectively. The decliners from South Asia were led by IT firm Infosys (INFY) and computer hardware maker Canaan (CAN), which dropped 2.9% and 1.4% respectively. They were followed by lender HDFC Bank (HDB) and It firm Wipro (WIT), which lost 1.1% and 0.6% respectively.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
